China's SFDA Sets New GMP Inspectional Guidelines
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State Food and Drug Administration issued revised good manufacturing practice inspectional guidelines Oct. 24 in an effort to increase quality systems standards for pharmaceutical manufacturers. The new guidelines are scheduled to go into effect Jan. 1, replacing the current GMP inspectional guidelines, which were implemented in 1998
You may also be interested in...
Benda’s Jiangling Plant Gets Production Approval
SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22
Benda’s Jiangling Plant Gets Production Approval
SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22
Sidley Austin Beijing Senior Counsel Chen Yang: An Interview with PharmAsia News
Chen Yang, senior counsel in Sidley Austin's Beijing office, recently spoke with PharmAsia News about recent developments in China that affect the pharmaceutical and medical device industries. Yang leads the firm's China life sciences practice. For the past 10 years, she has advised international companies on their investment projects and acquisition efforts in various Chinese industries and provided regulatory advice on intellectual property, life science, employment and other issues. She has also assisted China government agencies in several U.S. litigation matters.